Explosive Surge of 3.7 Billion CNY in Performance for Leading Dual-Targeted Therapy Company!

In an unprecedented achievement, a prominent biotech company has reported a staggering surge in performance, with revenues skyrocketing by 3.7 billion yuan. This remarkable feat marks Akeso Biopharma's first-ever annual profit since its inception. The extraordinary growth can be attributed to the successful sales of their PD-1/CTLA-4 dual-targeted therapy, which accounted for 83% of total product sales. Additionally, a substantial upfront payment of 500 million US dollars (equivalent to 2.9 billion yuan) for the overseas licensing of their PD-1/VEGF dual-targeted therapy played a significant role in this exceptional financial outcome.

Akeso Biopharma, known for its expertise in dual-targeted therapies, has emerged as a leader in the field, with six such therapies already in clinical development. One of their most successful products is the PD-1/CTLA-4 dual-targeted therapy, commercially known as AK104. Since its approval by the National Medical Products Administration (NMPA), AK104 has been primarily used for the treatment of recurrent or metastatic cervical cancer patients who have previously failed platinum-based chemotherapy. With its superior efficacy and favorable safety profile, AK104 garnered immense popularity among physicians, resulting in sales of 546 million yuan within the first six months of its market launch. Subsequently, sales reached an impressive 1.358 billion yuan in 2023. Furthermore, Akeso Biopharma's robust pipeline includes a wide range of innovative candidates targeting popular indications such as ADC, CD47, CD73, VEGFR2, IL-12/IL-23, and more.

Akeso Biopharma's success with AK104 has paved the way for their next growth engine, AK112, a PD-1/VEGF dual-targeted therapy. AK112, which combines tumor immunotherapy with anti-angiogenesis mechanisms, has already submitted its New Drug Application (NDA) and received priority review status. The promising phase 2 clinical data of AK112 led to a collaborative agreement with Summit Therapeutics, entailing a total transaction value of 5 billion US dollars (including a 500 million US dollar upfront payment) and double-digit royalty on net sales in the United States, Europe, Canada, and other regions.

Looking ahead, Akeso Biopharma's strategic focus includes expanding their product portfolio and exploring combination therapies. They are actively conducting over 20 clinical trials targeting indications such as gastric cancer, lung cancer, liver cancer, pancreatic cancer, and cervical cancer. Notably, they have initiated phase 3 trials for first-line treatment of advanced gastric cancer, and their phase 3 clinical study for first-line treatment of advanced cervical cancer has achieved the primary endpoint of progression-free survival (PFS). Additionally, they are conducting clinical studies for postoperative adjuvant treatment of hepatocellular carcinoma and first-line treatment of PD-L1-negative non-small cell lung cancer in combination with VEGFR2 monoclonal antibody, Plerixafor.

Aside from their impressive product pipeline, Akeso Biopharma has made significant investments in manufacturing capabilities. With an operational total capacity of 54,000 liters in locations such as Zhongshan and Guangzhou, they are poised to become the leading bio-pharmaceutical company in China with the largest intelligent production system. Moreover, they recognize the importance of participating in medical insurance negotiations to ensure broader patient access to their therapies.

The remarkable surge in performance by this leading dual-targeted therapy company underscores their dedication to advancing innovative treatments for cancer patients. With a successful flagship product and a promising pipeline, Akeso Biopharma is well-positioned for sustained growth. As they continue to push the boundaries of scientific research and expand their manufacturing capabilities, they are poised to make significant contributions to the field of oncology and improve patient outcomes worldwide.